Ginkgo Bioworks Holdings (DNABW) Cash from Investing Activities (2020 - 2026)
Ginkgo Bioworks Holdings (DNABW) reported Cash from Investing Activities of $23.1 million for Q1 2026, up 111.64% on a YoY basis from $10.9 million in Q1 2025, and down 75.68% quarter-over-quarter from $95.1 million in Q4 2025.
Ginkgo Bioworks Holdings (DNABW) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings has reported Cash from Investing Activities for 7 years, with the latest figure at $23.1 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 111.64% year-over-year to $23.1 million; the trailing twelve-month figure through Mar 2026 stood at -$18.5 million (up 92.58% YoY), and the FY2025 full-year result was -$240.3 million, down 286.09% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $23.1 million, down from $95.1 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $95.1 million in Q4 2025, with the low at -$198.7 million in Q1 2025.
- Historically, Cash from Investing Activities has averaged -$25.1 million across 5 years, with a median of -$14.7 million in 2022.
- The largest YoY upside for Cash from Investing Activities was 826.78% in 2025 against a maximum downside of 1540.66% in 2025.
- Ginkgo Bioworks Holdings' Cash from Investing Activities stood at $29.7 million in 2022, then tumbled by 256.94% to -$46.7 million in 2023, then surged by 71.97% to -$13.1 million in 2024, then surged by 826.78% to $95.1 million in 2025, then tumbled by 75.68% to $23.1 million in 2026.
- The last three Cash from Investing Activities figures came in at $23.1 million (Q1 2026), $95.1 million (Q4 2025), and -$72.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Ginkgo Bioworks Holdings | - | - | 16.38 Mn | 23.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.13 Mn |
| Mar 31, 2026 | 23.13 Mn |
| Dec 31, 2025 | 95.10 Mn |
| Dec 31, 2025 | 95.10 Mn |
| Sep 30, 2025 | -72.82 Mn |
| Sep 30, 2025 | -72.82 Mn |
| Jun 30, 2025 | -63.89 Mn |
| Jun 30, 2025 | -63.89 Mn |
| Mar 31, 2025 | -198.68 Mn |
| Mar 31, 2025 | -198.68 Mn |
| Dec 31, 2024 | -13.09 Mn |
| Dec 31, 2024 | -13.09 Mn |
| Sep 30, 2024 | -10.20 Mn |
| Sep 30, 2024 | -10.20 Mn |
| Jun 30, 2024 | -26.84 Mn |
| Jun 30, 2024 | -26.84 Mn |
| Mar 31, 2024 | -12.11 Mn |
| Mar 31, 2024 | -12.11 Mn |
| Dec 31, 2023 | -46.67 Mn |
| Dec 31, 2023 | -46.67 Mn |